# **Amendments to the Claims**

This claim listing will replace all prior versions of claims and claim listings in the application:

## 1. (Original) A compound of formula I:

$$R^3$$
 $R^4$ 
 $R^5$ 
 $R^6$ 
 $R^7$ 

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof,

wherein: R<sup>1</sup> is selected from H, a halogen, and a methyl optionally substituted with one or more fluorines;

 $R^2$ ,  $R^3$ ,  $R^4$ , and  $R^5$  are each independently selected from H, a halogen, an amide, a sulfonamide, a  $C_1$ - $C_5$  alkyl optionally substituted with one or more halogens, a  $C_2$ - $C_5$  alkynyl optionally substituted with one or more halogens, a  $C_2$ - $C_5$  alkynyl optionally substituted with one or more halogens, a  $C_1$ - $C_4$  alkoxy optionally substituted with one or more halogens and a  $C_1$ - $C_4$  thioalkyl optionally substituted with one or more halogens, a  $C_2$ - $C_4$  thioalkyl optionally substituted with one or more halogens, and a  $C_2$ - $C_4$  thioalkynyl optionally substituted with one or more halogens; or

R<sup>2</sup> and R<sup>3</sup> taken together form a 3 to 8 membered carbocyclic or heterocyclic ring, optionally substituted with one or more fluorines; or

R<sup>3</sup> and R<sup>4</sup> taken together form a 5 to 6 membered carbocyclic or heterocyclic ring, optionally substituted with one or more fluorines; or

R<sup>4</sup> and R<sup>5</sup> taken together form a 5 to 6 membered carbocyclic or heterocyclic ring, optionally substituted with one or more fluorines;

 $R^6$  is selected from H, a  $C_1$ - $C_5$  alkyl optionally substituted with one or more halogens, a  $C_2$ - $C_5$  alkenyl optionally substituted with one or more halogens, and a  $C_2$ - $C_5$  alkynyl optionally substituted with one or more halogens;

R<sup>7</sup> is selected from CH<sub>2</sub>OH, CHO, COOH and a group of formula (a):

$$R_8$$
  $R_9$  (a) ;

wherein R<sup>8</sup> and R<sup>9</sup> are each independently selected from H, OH and a methyl optionally substituted with one or more fluorines;

n is 1, 2 or 3;

X is O, NR<sup>10</sup> or S; and

 $R^{10}$  is selected from H, a  $C_1$ -  $C_5$  alkyl optionally substituted with one or more halogens, a  $C_2$ - $C_5$  alkenyl optionally substituted with one or more halogens, and a  $C_2$ - $C_5$  alkynyl optionally substituted with one or more halogens.

2. (Original) A compound according to claim 1, wherein:

R<sup>1</sup> is selected from H and a C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with one or more halogens;

R<sup>6</sup> is selected from H and a C<sub>1</sub>-C<sub>3</sub> alkyl group optionally substituted with one or more halogen;

 $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are each independently selected from H, a halogen, a  $C_1$ - $C_3$  alkyl optionally substituted with one or more halogens, a  $C_2$ - $C_3$  alkenyl optionally substituted with one or more halogens, a  $C_2$ - $C_3$  alkynyl optionally substituted with one or more halogens, a  $C_1$ - $C_3$  alkoxy optionally substituted with one or more halogens, a  $C_1$ - $C_3$  thioalkyl optionally

substituted with one or more halogens, a  $C_2$ - $C_3$  thioalkenyl optionally substituted with one or more halogens, and a  $C_2$ - $C_3$  thioalkynyl, optionally substituted with one or more halogens; or

R<sup>2</sup> and R<sup>3</sup> taken together form a 4 to 7 membered carbocyclic or heterocyclic ring optionally substituted with one or more halogens; or

R<sup>3</sup> and R<sup>4</sup> taken together form a 5 to 6 membered carbocyclic or heterocyclic ring optionally substituted with one or more halogens.

3. (Original) A compound according to claim 2, wherein:

 $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  each independently is selected from the group H,  $C_1$ - $C_2$  alkyl optionally substituted with one or more halogens, a  $C_2$  alkenyl group optionally substituted with one or more halogens, an  $C_1$ - $C_2$  alkoxy group optionally substituted with one or more halogens, and a  $C_1$ - $C_2$  thioalkyl group optionally substituted with one or more halogens; or

R<sup>2</sup> and R<sup>3</sup> taken together form a 5 to 6 membered carbocyclic or ring optionally substituted with one or more fluorines; or

R<sup>3</sup> and R<sup>4</sup> taken together form a 5 to 6 membered carbocyclic ring optionally substituted with one or more fluorines; or

R<sup>4</sup> and R<sup>5</sup> taken together form a 5 to 6 membered carbocyclic ring optionally substituted with one or more fluorines.

- 4. (Original) A compound according to claim 1, wherein:
   R<sup>2</sup> and R<sup>3</sup> are each independently selected from H and methyl; or
   R<sup>2</sup> and R<sup>3</sup> taken together from a 3 to 8 membered carbocyclic ring.
- 5. (Original) A compound according to claim 1, wherein:  $R^3 \text{ and } R^4 \text{ are each independently methyl; or}$   $R^3 \text{ and } R^4 \text{ taken together from a 3 to 8 membered carboxylic ring.}$

- 6. (Original) A compound according to claim 1, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are each independently selected from H and a methyl optionally substituted with one or more fluorines.
- 7. (Currently amended) A compound according to any one of claims 2, 3, 4 and 6 wherein  $R^5$  and  $R^6$  are each H.
- 8. (Original) A compound according to claim 6, wherein:  $R^7 \text{ is } C(R^8)(R^9)(OOH),$

wherein  $R^8$  and  $R^9$  are each independently selected from H and a methyl optionally substituted with one or more fluorines.

- 9. (Original) A compound selected from: 4-(2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)benzoic acid, 4-(2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)phenylacetic acid, 4-(8,9-dimethyl-2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)benzoic acid, 4-(8,9-cyclopentano-2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)benzoic acid, 4-(9,10-benzo-2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)benzoic acid, 4-(2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinolin-4-yl)benzoic acid, 4-(2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinolin-4-yl)phenylacetic acid, and 4-(9,10-benzo-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinolin-4-yl)benzoic acid.
- 10. (Original) A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 1.
- 11. (Canceled)
- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)
- 15. (Canceled)

- 16. (Canceled)
- 17. (Canceled)
- 18. (Canceled)
- 19. (Original) A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity, cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 1.
- 20. (Canceled)
- 21. (Canceled)
- 22. (Canceled)
- 23. (Canceled)
- 24. (Canceled)
- 25. (Canceled)
- 26. (Canceled)
- 27. (Canceled)